

Lyme Disease Committee meeting 4

Date: 24/01/2016

Location: Boardroom, National Guideline Centre, 180 Great Portland Street,
London, W1W 5QZ

Minutes: Confirmed

Committee members present:	
Saul Faust (SF, Chair)	(Present for notes 1–5)
Srini Bandi (SB)	(Present for notes 1–5)
Stephen Barton (SBa)	(Present for notes 1–5)
Nick Beeching (NB)	(Present for notes 1–4a, 4c–5)
Robin Brittain-Long (RBL)	(Present for notes 1–5)
Tim Brooks (TB)	(Present for notes 1–4a, 4c–5)
Scott Hackett (SH)	(Present for notes 1–5)
Cheryl Hemingway (CH)	(Present for notes 3–5)
Neil Hopkinson (NH)	(Present for notes 1–5)
Veronica Hughes (VH)	(Present for notes 1–5)
Stella Huyshe-Shires (SHS)	(Present for notes 1–5)
Melissa McCullough (MM)	(Present for notes 1–5 via phone and WebEx)
Caroline Rayment (CR)	(Present for notes 4–5)
David Stephens (DS)	(Present for notes 1–5)

In attendance:		
Catharine Baden-Daintree (CBD)	Senior Medical Editor, NICE	(Present for notes 1–5)
Maria Cruickshank (MC)	Research Fellow, NGC	(Present for notes 1–5)
Meredith Faust (MF)	Document Editor/Process Assistant, NGC	(Present for notes 1–5)
Andreas Freitag (AF)	Senior Research Fellow, NGC	(Present for notes 1–5)
Samantha Jones (SJ)	Project Manager, NGC	(Present for notes 1–5)
Sophia Kemmis-Betty (SKB)	Senior Health Economist, NGC	(Present for notes 1–5)
Norma O’Flynn (NOF)	Guideline Lead, NGC	(Present for notes 1–5)

Apologies:	
Nick Davies (ND)	Consultant Neurologist, Co-opted Expert
Ben Doak (BD)	Guideline Commissioning Manager, NICE
Jill Cobb (JC)	Information Specialist, NGC
Rebecca Houghton (RH)	Clinical Trainee, NGC

1. Welcome and objectives for the meeting

The Chair welcomed the committee members and attendees to the fourth meeting of the Lyme disease Guideline Committee. The committee members and attendees introduced themselves.

The Chair informed the committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included diagnostic tests, health economics and draft review protocols.

2. Confirmation of matter under discussion and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Lyme disease diagnostic tests, health economics and draft review protocols.

The Chair asked everyone to declare verbally any interests that have arisen since the last meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Robin Brittain-Long	Consultant Physician, Acute Medicine and Infectious Diseases, Aberdeen Royal Infirmary	I am attending a meeting in Madrid, Spain, sponsored by the pharmaceutical company Pfizer. Pfizer sponsors my travel and accommodation. It is Masterclass VII Madrid meeting regarding the use of newer anticoagulants–NOACs–to prevent stroke in nonvalvular atrial fibrillation.	Non-personal financial non-specific	Declare and participate.

The Chair and a senior member of the Developer's team noted that the following members would not participate in a part of the meeting:

Nick Beeching and Tim Brooks both have previously declared interests in diagnostic method; therefore, they were asked to act as experts to the group and to withdraw from the group for the discussion of recommendations.

3. Minutes of the last meetings
<p>The Chair asked the committee if it wanted to change the minutes of the last meeting. The committee agreed that the minutes were a true and accurate account of the meetings.</p> <p>The Chair confirmed that all matters arising had been completed or were in hand.</p>
4. Presentations and Discussions
<p>a) AF presented the initial, combination and confirmatory tests. The committee discussed the evidence presented.</p> <p>b) The committee discussed the diagnostic tests. TB and NB were asked to leave for a short period to allow the remaining committee members to discuss the evidence and recommendations separately.</p> <p>c) SKB briefly discussed the health economics concerning diagnostic tests.</p> <p>d) The committee discussed the draft protocols for the management review questions.</p>
5. Any other business
None.

Date of next meeting: 21/02/17

Location of next meeting: Boardroom, National Guideline Centre, 180 Great Portland Street, London, W1W 5QZ